Clinical Evidence For HAI Therapy For Intrahepatic Cholangiocarcinoma

Hepatic Arterial Infusion Pump Chemotherapy In Patients With Advanced Intrahepatic Colangiocarcinoma Confined To The Liver: A Multicenter Phase II Trial

Franssen S, et al. | American Society of Clinical Oncology 2024 GI Cancers Symposium

A prospective single-arm, multi-center study reported a 33% 3-year overall survival rate for liver-confined iCCA patients treated with HAI therapy vs. 3% when treated with Gem-Cis systemic chemotherapy alone.

Hepatic Arterial Infusion Pump Chemotherapy For Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review And Meta-Analysis

Holster J, et al. | Annals of Surgical Oncology, 2022

A systemic review and meta-analysis of 9 publications, including 154 unique patients, demonstrated HAI therapy was associated with a 39.5% 3-year overall survival rate compared with < 3% for gemcitabine-cisplatin systemic chemotherapy alone as reported in the ABC trials.

Assessment Of Hepatic Arterial Infusion Of Floxuridine In Combination With Systemic Gemcitabine And Oxaliplatin In Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial

Cercek A, et al. | JAMA Oncology, 2020

A single-arm, prospective, phase II trial showed a median overall survival of 25 months and a 1-year survival rate of 89%, a dramatic improvement in overall survival, independent of resectability for unresectable iCCA patients treated with HAI therapy.